-
Mashup Score: 2Study Finds No Differences Between Adalimumab, Biosimilar for Inflammatory Bowel Disease - 1 month(s) ago
There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
Study finds biosimilar adalimumab (Idacio) as effective and safe as Humira for treating inflammatory bowel disease. #IBD #Biosimilars #Adalimumab Read More: https://t.co/UZqQiZnmHu